April 14, 2015 09:00 ET

DIAGNOS Announces Licensing Deal With Clinique Hamouche in Algeria

BROSSARD, QUEBEC--(Marketwired - April 14, 2015) - DIAGNOS Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announces today a deal with Clinique Hamouche in Algeria.

Clinique Hamouche provides vision correction, eye surgery, plastic surgery, and various other related services and offers the latest laser technologies for the ophthalmology and aesthetic services it provides. DIAGNOS will be providing its proprietary telemedicine software, CARA, and retina image interpretation to help the clinic in adding an additional service for its patients, retina screening. This preliminary contract is valid for one year with possibility for renewal and expansion.

"Clinique Hamouche offers a multitude of services related to ophthalmology and already owns all of the equipment required for retina screening. Recognizing the utility of CARA and the retinal analysis services DIAGNOS provides, the clinic has decided to add retina screening to its list of services through the use of DIAGNOS' services. DIAGNOS will integrate CARA with the clinic's existing infrastructure, providing a seamless and effortless transition to offering retina screening to their patients," said André Larente, DIAGNOS' President.


Founded in 1998, DIAGNOS is a publicly traded Canadian corporation, with a mission to commercialize technologies to improving decision making processes in different sectors. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.

About DIAGNOS Healthcare

DIAGNOS Healthcare is a business division with DIAGNOS Inc., achieving international recognition as leader in healthcare technical services including, screening, software and algorithm development, data analysis, and image processing. Through its Healthcare division, DIAGNOS offers turn-key diabetic retinopathy screening services to patients in various locations around the world.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information on DIAGNOS, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com.

Contact Information

  • DIAGNOS Inc.
    Andre Larente
    (450) 678-8882 ext 224